Online inquiry

IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7110MR)

This product GTTS-WQ7110MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL6&IL6R gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000600.5; NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569; 3570
UniProt ID P05231; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ7110MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9496MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J2898A
GTTS-WQ4704MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ2266MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ4947MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ11069MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ8400MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ5877MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ11691MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MHAB5553A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW